TIDMVLG

RNS Number : 6940A

Venture Life Group PLC

25 May 2023

25 May 2023

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Director Dealings

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that Paul Mcgreevy, Non-Executive Chairman, today purchased 125,276 ordinary shares of 0.3p each in the Company ("Ordinary Shares") at a volume weighted average price of 39.91 pence per Ordinary Share.

Following this purchase, Mr Mcgreevy beneficially holds 689,866 Ordinary Shares representing 0.55 per cent. of the Company's issued share capital.

For further information, please contact:

 
                                                     +44 (0) 1344 
 Venture Life Group PLC                               578004 
 Jerry Randall, Chief Executive Officer 
  Daniel Wells, Chief Financial Officer 
 
                                                       +44 (0) 20 7397 
   Cenkos Securities plc (Nomad and Broker)            8900 
 Stephen Keys / Camilla Hume 
 Russell Kerr / Michael Johnson (Sales) 
 
   Singer Capital Markets (Joint Broker) 
   Shaun Dobson / Alaina Wong (Corporate Finance)      +44 (0) 20 7496 
   Jonathan Dighe (Sales)                              3000

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands, these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies for consumer healthcare products, primarily medical devices.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

 
      Details of the person discharging managerial responsibilities 
  1    / person closely associated 
 a)   Name                        Paul Mcgreevy 
     --------------------------  ---------------------------------------- 
      Reason for the notification 
  2 
     -------------------------------------------------------------------- 
 a)   Position/status             Non-Executive Chariman 
     --------------------------  ---------------------------------------- 
 b)   Initial notification        Initial notification 
       /Amendment 
     --------------------------  ---------------------------------------- 
      Details of the issuer, emission allowance market participant, 
  3    auction platform, auctioneer or auction monitor 
     -------------------------------------------------------------------- 
 a)   Name                        Venture Life Group plc 
     --------------------------  ---------------------------------------- 
 b)   LEI                         213800S8CZUPLAB2KC70 
     --------------------------  ---------------------------------------- 
      Details of the transaction(s): section to be repeated 
  4    for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     -------------------------------------------------------------------- 
 a)   Description of the          Ordinary Shares of 0.3p each in Venture 
       financial instrument,       Life Group plc 
       type of instrument 
 
 
       Identification code         GB00BFPM8908 
     --------------------------  ---------------------------------------- 
 b)   Nature of the transaction   Purchase of ordinary shares 
     --------------------------  ---------------------------------------- 
 c)   Price(s) and volume(s)      50,276 ordinary shares at 39.78 pence 
                                   per share 
                                   75,000 ordinary shares at 40.00 pence 
                                   per share 
     --------------------------  ---------------------------------------- 
 d)   Aggregated information      n/a 
 
 
       - Aggregated volume 
 
 
       - Price 
     --------------------------  ---------------------------------------- 
 e)   Date of the transaction     25 May 2023 
     --------------------------  ---------------------------------------- 
 f)   Place of the transaction    London Stock Exchange 
     --------------------------  ----------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHLELFLXELEBBF

(END) Dow Jones Newswires

May 25, 2023 08:54 ET (12:54 GMT)

Venture Life (LSE:VLG)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Venture Life Charts.
Venture Life (LSE:VLG)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Venture Life Charts.